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Analysis of Complete Remission in Lupus Patients over a period of 32 years. 
Medina-Quiñones CV;  Ramos L;  Ruiz P; Isenberg DA 
BACKGROUND: Systemic Lupus Erythematosus (SLE) is characterized by an unpredictable and 
fluctuating course. Although various methods have been developed to measure disease 
activity, there is still a lack of consensus about the optimal criteria for SLE remission. 
The principal aim of our study was to identify the number of lupus patients achieving a 
complete remission (implying that for 3 years there were no clinical or serological features and 
no treatment with steroids and immunosuppressive drugs) in a single cohort of patients 
followed for a period of up to 32 years. In addition, we have identified patients in clinical but 
not serological remission (known as serologically active, clinically quiescent disease (SACQ)) 
and vice versa. We were particularly interested to determine the factors associated with 
complete remission.  
METHODS: Eligible patients were followed up in the University College Hospital Lupus cohort 
from January 1978 until December 2010 for a period of at least 3 years. Complete remission 
was defined as a period of at least 3 years with clinical inactivity (BILAG scores of C, D or E 
only) and laboratory remission (no antibodies to dsDNA and normal complement C3 levels)  
and being off-treatment with corticosteroids and immunosuppressants. Antimalarials and 
nonsteroidal anti-inflammatory were allowed.  
RESULTS: Of 624 lupus patients at our hospital, a total of 532 patients met the strict inclusion 
criteria for the study. Of these 532 patients, 77 patients (14.5%) achieved complete remission 
for at least 3 years, 23 (4.3%) achieved complete remission for a minimum period of 10 years. 
Ten of these 77 patients were subsequently lost to follow up, and interestingly flares occurred 
subsequently in 15 of the 67 remaining patients (22.4%). Three patients relapsed after the 
tenth year of remission. Forty-five (8.5%) patients fulfilled the requirement for SACQ, and 
sixty-six (12.4%) patients achieved only serological remission. 
 CONCLUSIONS: Our study indicated that 14.5% of lupus patients achieved a complete 
remission for three years. However, flares may continue to occur beyond ten years of 
remission. Long term follow up of SLE is thus mandatory.  
 
 
 
SIGNIFICANCE AND INNOVATION  
 
Patients with SLE often develop the disease in their teenage years/early 20s. They are keen to 
get prognostic information. Most studies limit their outcome reporting to 5-10 year periods. In 
this study we describe the long-term follow-up over a period of 32 years focusing on a key 
question about whether patients who go into full clinical and serologic remission (for 3 years) 
will remain in remission subsequently. Our data extracted from our very long-term and careful 
follow-up indicates that 22.4% of patients will flare even after 3 years of remission. We believe 
these data are important and will help guide what rheumatologists say to their patients with 
lupus.  
  
INTRODUCTION: 
Systemic Lupus Erythematosus (SLE) is characterized by an unpredictable and fluctuating 
course with relapses and remissions over many years. However, the prognosis and survival of 
SLE patients have improved significantly in the last decade 1.  
Few reports describing long-term remission rates, in excess of fifteen years exist, and also 
there is inadequate knowledge about predictors of relapse. 
Some patients may be clinically asymptomatic without steroids, but have persistently raised 
anti-dsDNA or anti-nucleosome antibodies also known as serologically active clinically 
quiescent (SACQ) 2,3. 
Various indices have been developed to measure disease activity e.g. the British Isles Lupus 
Assessment (BILAG), the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) and 
the European Community Lupus Activity Measure (ECLAM), and have been known to be 
reasonably equivalent 4, 5. However, there is still a lack of consensus about the optimal criteria 
to define SLE remission. 
The aim of our study was to identify, in retrospect, the number of lupus patients achieving a 
complete remission (minimum of 3 years) in a single cohort of patients followed for periods of 
up to 32 years at University College Hospital. The time point chosen was arbitory, but we felt 
as clinicians that any patient lacking clinical features of lupus for 3 years would, at least 
ostensibly, tend to encourage us to believe that the disease might truly have abated. In 
addition, we noted the frequency of patients that achieved clinical remission or prolonged 
serologically active clinically quiescent disease (SACQ), and those who only achieved 
serological remission. We also sought to determine disease characteristics associated with 
complete remission (no clinical or serological activity and on nothing more than 
Hydroxychlorquine). 
 
MATERIALS AND METHODS: 
PATIENTS 
We enrolled patients fulfilling the revised ACR criteria for classification of SLE and the data we 
have recorded about them were retrospectively assessed 6.  
Eligible patients were followed up principally at University College Hospital from January 1978 
until December 2010 for a period of at least 3 years and were required to have made at least 
one visit per year.  
DATA 
The study variables included sex, ethnicity, age at the time of SLE onset, time of follow-up, 
duration of disease, time to achieve remission, duration of remission, existence of flare, the 
presence of mucocutaneous involvement (rash, alopecia, mucosal ulcers), musculoskeletal 
involvement, cardiopulmonary manifestations (serositis, shrinking lung syndrome, alveolar 
haemorrhage), central nervous system (CNS) disease (including psychosis, seizures, paresis or 
paralysis, and cranial nerve involvement), kidney involvement (nephritis documented 
invariably by biopsy) , haematological manifestations (thrombocytopenia, Antiphospholipid 
syndrome), vasculitis (documented by biopsy), laboratory results (anti-double stranded DNA 
antibodies, complement C3) and medication. 
MEASUREMENTS 
Anti-dsDNA antibodies were considered to be positive if the patient had a ELISA level result 
(Shield Diagnostics, Dundee, UK) above the upper limit of normal (>50 IU) on at least two 
occasions.  
Serum C3 levels were measured by laser nephelometry.  
The method of measuring disease activity was the classic BILAG system, which is also sensitive 
to disease flares 5.  
OUTCOME MEASURES 
The primary goal was to assess the complete remission rate in our lupus patients during a 
minimum period of three years. We also determined the frequency of patients that achieved 
serological remission only, and clinical remission (also known as SACQ). Other assessed 
outcomes were flares, death rate, and disease characteristics associated with complete 
remission 
DEFINITIONS 
Complete remission was defined as a minimum 3-year consecutive period of no disease 
activity, specifically patients who had a score of C, D or E on the BILAG index only, were off 
steroids and immunosuppressant drugs, except antimalarials which were permissible, had 
normal laboratory tests (no antibodies dsDNA and normal serum levels of C3 complement), 
and had not had a recurrence or any other reason for treatment failure before the time point 
of interest. 
Clinical remission or SACQ was defined as a score of C, D or E on the BILAG index and absence 
of pharmacotherapy (corticosteroids and immunosuppressants save antimalarials) but 
remained an active serologic profile (low C3 complement level and/or high antidoublestranded 
DNA antibody levels) for at least 3 consecutive years. 
Serological remission was characterized by normal complement C3 and anti-ds DNA antibody 
levels but with persistent clinical activity (score of A or B on the BILAG index, and/or treatment 
with steroids or immunosuppressive drugs) for at least 3 consecutive years. 
Clinical Flare (or relapse) was defined by the development of score A or B on the BILAG index, 
with or without a low C3 complement serum level or positive Anti-dsDNA result. 
Serological Flare (or relapse) required decreased level of C3 complement and/or a high Anti-
dsDNA antibody result, in the group of patients who have achieved only serological remission 
but remained clinically active. 
 
STATISTICAL ANALYSIS 
We used the Statistical Package for the Social Sciences (SPSS) for all conventional analyses. The 
results were described as the median (maximum and minimum range). Continuous variables 
were analyzed (by univariate analysis) using nonparametric Kruskal-Wallis tests. Group data 
were compared by X2 test. Only associations with P value <0.05 were considered statistically 
significant.  
 
RESULTS 
We excluded those who had been diagnosed before 1978 (37 patients) or after 2010 (8 
patients), and those for whom we had insufficient data or irregular follow-up because some 
patients moved away either within the UK or overseas (47 patients). Of 624 lupus patients at 
our hospital, 532 patients were followed for a 3 year-period minimum and also required at 
least one visit per year (Table 1). 
 
The number of patients who did not achieve clinical and serological remission was 344 (64.7%). 
Nine patients were taking DMARD`s with or without steroids due to other underlying disease   
(3 for kidney transplant, 2 for psoriasis, 1 for bowel inflammatory disease, 1 for primary biliary 
cirrhosis, 1 for primary pulmonary hypertension and 1 for Lymphoma non-Hodgkin`s) . 
Seventy-seven patients (14.5%) achieved complete remission as defined in the Methods for at 
least 3 years. Complete remission occurred a median time of 9 years after the time of being 
diagnosed (the minimum and maximum range of time since diagnosis was 0 – 27 years). The 
median time of remission was 7 years (the minimum and maximum range of time was 3 – 24 
years), and interestingly 23 patients (4.3%) achieved complete remission for a minimum period 
of 10 years.  
Of the 77 patients who had at least 3-year remission, 10 were lost to follow-up while still in 
remission. There was at least one flare in 15 of these 67 remaining patients (22.4%). Of these 
flares, 10 were simply clinical whereas 5 had alterations in laboratory and clinical features. 
Three patients relapsed after the tenth year of remission (at 12, 16 and 18 years).   
Forty-five (8.5%) patients fulfilled the requirement for clinical remission (SACQ), though ten 
patients had a flare after 3-year time. One patient was lost follow-up after the sixth year of 
remission. (Figure 1). 
 
In the group of 77 patients who had a complete remission, forty-eight (62.3%) were still on 
hydroxychloroquine and twenty-nine (37.7%) were off-treatment. Thus only 5.5% of our SLE 
patients cohort were in complete remission without any medication. In the group of 45 
patients who achieved only clinical remission (SACQ), twenty-eight (62.2%) were still taking 
hydroxychloroquine and seventeen (37.8%) had withdrawal of therapy.  
Sixty-six (12.4%) patients only achieved a serological remission, and 14 had serological 
relapses.  All remained clinically active. Four patients were lost follow-up after achieving the 
third, fourth, fifth and sixth year of serological remission respectively. 
We could not identify a trigger that caused relapses in 69% of our patients. A percentage of 
15% of the patients relapsed immediately after pregnancy and 8% flared post-infections. We 
did not find any statistically significant association between the frequency of relapses and 
clinical manifestations such as renal, mucocutaneous, cardiopulmonary, musculoskeletal, 
neurological, hematological, vasculitis or the presence of overlap syndromes. 
A comparison of the baseline characteristics and clinical parameters of the patients who 
achieved complete remission, clinical remission (SACQ), serological remission and absence of 
remission is shown in Table 2 and Table 3, respectively. 
 
We could not determine, accurately, an association between the likelihood of remission and 
sex and ethnicity because of the small size sample. However, there is a higher frequency 
among non-Caucasian patients in the non-remission group.   
Patients who went into complete remission were older at the time of diagnosis (p<0.001) and 
had a longer disease duration (p<0.001).  
Seventy-one deaths of patients included in our study were reported and its main causes were 
infections (28.2%), cancer (23.9%) and atherosclerosis (12.7%). The median age at death was 
45 years (range of age at death was 16 years – 88 years). In the complete remission group only 
four patients died whereas 61 deaths occurred in those who never achieved remission 
(p<0.001). 
Achieving remission is further negatively influenced by renal (p<0.001), neurological (p=0.002) 
and cardiopulmonary involvement (p<0.001). Patients with major mucocutaneous involvement 
also have a lower likelihood of achieving remission (p<0.05). No statistically significant 
difference was found in Sjogren`s syndrome (p=0.230).  
 
DISCUSSION 
We found that 14.5% (n=77) of our lupus patients achieved a complete remission for three 
years. In addition, only 5.5% (29 patients) of our lupus cohort were in complete remission 
without any medication (including antimalarials). Previous studies have reported different 
values of incidence and prevalence among patients who achieve remission(which in most 
publications means clinical remission) in their respective populations. The lack of consensus 
about the criteria for remission has influenced in these discordant results. 
In 1964, Dubois and Tuffanelli described a high percentage of remission  (35%) in a study of 
520 patients during a period of follow-up to 13 years, without specifying the remission criteria 
they used. They also determined that nine patients had spontaneous remission that lasted at 
least 10 years of duration8. 
Tozman et al.9 published one of the first prospective studies about complete remission in SLE 
patients, describing a proportion of 4/160 (2.5%) patients achieving complete remission and 
being off immunosuppressants for a median time of 75-months follow-up, in spite of a history 
of renal involvement. 
Formiga et al. 10 reported that 24 of 100 Caucasian patients achieved remission  at least for a 
year and remained in remission for an average time of 55 months. They used the SLEDAI score 
to assess activity since the onset of disease, and found that higher SLEDAI scores correlated 
with later remission. However, even by those with severe disease could go into remission. 
Despite the fact that their percentage of patients in remission is bigger than ours, our study 
population has greater ethnic diversity, given that Caucasians have better prognosis. In 
addition, 17 of 24 (70%) remained in remission, similar to our findings in which 52 of our 77 
lupus patients (68%) have remained in remission.   
Drenkard et al.11 determined that 156 of 667 (23.4%) patients achieved remission  without any 
therapy (even antimalarials) for a minimum of one-year period, and almost half of these 
patients (12%) remained in remission for at least 5 years.  Twenty-nine patients of our lupus 
cohort went into remission without any medication (including antimalarials) at least for 3 
years. However, they did not use a conventional index to measure activity such as SLEDAI or 
BILAG, and they were not as strict about changes in laboratory results to classify patients into 
different types of remission. They found that 41/156 patients with renal involvement and 
19/156 patients with neurological disease achieved clinical remission. 
Another study identified thirteen (4%) of 305 patients with serological and clinical remission12. 
Five of these patients remained in complete remission for a minimum period of 3 years. 
Nevertheless, their remission criteria were different from ours. They performed an ANA test 
instead of measuring levels of DNA binding, and also included asymptomatic patients who 
were taking a low dose of corticosteroids in the group of remission. Eight of these thirteen 
patients (2.6%) were not receiving treatment. They, like us, found a lower prevalence of kidney 
and central nervous system involvement in those going into remission. Unfortunately, we 
restricted our serological studies to dsDNA antibodies and serum levels of C3 complement, so 
we do not have available information on ANA. 
In 2005, Urowitz et al.13 found that only 12 of 703 patients (1.7%) fulfilled criteria for 
prolonged complete remission (SLEDAI=0) after 5 years without therapy. Their research 
demonstrated as might be expected, that being less restrictive with respect to the remission 
criteria (permitting antimalarials as treatment), increases frequency of achieving remission. 
We excluded from the patients in complete remission and SACQ those who had become 
asymptomatic, but who were still taking treatment, including a minimal dose of steroids, so no 
drug might contribute or affect the result. There is evidence which supports the use of 
antimalarials for the prevention of flares or recurrences 14, 15. Sixty-two percent of our patients 
who achieved remission were taking antimalarials.  
Gladman et al. found 14 of 180 (7.8%) patients who were in clinical remission with persistent 
laboratory abnormalities (SACQ), were off all medication for 4 years 2. We determined that 45 
of our lupus patients (8.5%) were in SACQ and 10 of them subsequently relapsed.  
Further studies have shown that patients with a prolonged SACQ disease accumulate less 
damage supporting the idea of managing them with close monitoring without therapy during 
this period 16, 17. 
Some studies based on the oncology literature chose five years for defining a period of 
remission 13. Although arbitrary we felt that a 3-year period with no clinical or serological 
abnormalities and on no major therapy would be sufficient to convince most rheumatologist 
and SLE patients that a viable remission had been achieved. However, there is no agreement 
about time of remission. Encouragingly, we found that 23 patients (4.3%) achieved remission 
beyond 10 years. 
Previous studies have used an SLEDAI score to evaluate disease activity 10, 13. However, in our 
study, disease activity was measured by BILAG. The BILAG index is a useful and reliable 
instrument to measure disease activity for each organ-based system 18. Moreover, the BILAG 
index correlates highly with other methods of measuring activity such as SLEDAI, and BILAG 
can easily detect flares 4, 7. 
 
Although it could be argued that by allowing our lupus patients with BILAG C scores to be 
included in what we have referred to as “clinical remission”, this group of patients might more 
accurately be referred to as low/no activity. In reality however, many BILAG C scores were 
achieved rather easily eg a very transient photosensitive induced rash or a clinical feature no 
longer regarded as reflecting disease activity eg the presence of Raynaud’s phenomenon or 
items which are in fact damage items eg a fixed livedo reticularis rash or a tendon contracture 
or an avascular necrosis. Indeed the ease with which a C score could be obtained in many of 
the organs or systems in the orginal BILAG activity index led the BILAG group to modify its 
index which is now known as BILAG-2004. 19 
 
Another limitation in the study is the challenge we faced to link different types of 
immunosuppression to the various types of remission. We have not found it possible to 
achieve this because many of the patients were taking multiple immunosuppressives either 
concomitantly or sequentially, some were treated with Rituximab and immunosuppression and 
about a third were co-managed at other hospitals to which we do not have ready access to 
patient notes.  
 Similar to previous studies, our findings confirmed that those who had an increased probability 
of complete remission were older at the time of diagnosis and had longer disease duration at 
study 11, 13. Currently, we have very limited data about menopausal status of the female 
patients, so that although of interest, we cannot easily relate it to disease remission. 
Our result agreed with those of Gladman et al.2 with respect to the lower frequency of 
cutaneous, renal and neuropsychiatric involvement in patients achieving clinical remission. 
Heller et al. reported similar findings in 1985 12. In addition, we determined that achieving 
remission is negatively impacted by cardiopulmonary involvement.  
One important association was that patients who did undergo remission were less likely to die 
than those who did not, highlighting the importance of achieving remission. It is known that 
the survival in those who do not achieve remission is impaired 11.  
Our study is limited in that we did not assess the cumulative dosage and length of 
immunosuppressive therapy and total corticosteroid use over the entire follow-up period.  
There were 15 flares, and 3 of 77 of our SLE patients had relapses after 10 years of complete 
remission. We thus emphasize the importance of continued close monitoring because it is 
even almost impossible to predict disease progression. We did not however assess the 
frequency of patients who have relapsed and remitted again and the time that have passed till 
they suffered new flares. 
Even though, we could not evaluate association between the probability of the several types of 
remission and sex and ethnicity because of the small size sample, we found a significant 
number of non-Caucasian patients in the group who did not achieve  remission and those who 
achieved only serological remission. Nossent et al. 20 and Rekha Lopez et al. 21 demonstrated 
poorer prognosis among Afro-Caribbean lupus patients with higher disease activity measures. 
White patients have a milder disease compared to those with African or Hispanic ethnicity 20, 21, 
22.. 
A large number of patients (n=92) did not meet the inclusion criteria because most of them 
moved abroad or had a premature unknown death or were attended other clinics in the UK. 
Additionally, those who were diagnosed after 2010 and before 1978 were excluded in order to 
avoid a bias because of the influence of an older and probably postmenopausal age. Moreover, 
patients who were diagnosed after 2010 had insufficient follow-up time to meet our criteria 
for remission. 
Sadly, we did not assess the cumulative disease activity or cumulative damage during the 
follow-up. The aim of our study was to describe the characteristics of patients at baseline in 
order to determine if some of them could be used as a predictor of disease outcomes. The full 
range of factors or features of the patients that may influence in remission and recurrence 
have not yet been determined.  
 
In conclusion we found that 14.5% of lupus patients achieved a complete remission after three 
years. Although harder to achieve in those patients with major organ involvement, it can 
occur. However, flares may continue happening beyond ten years of remission. Long term 
follow up of SLE is thus mandatory. 
 
REFERENCES: 
1. Chambers SA, Allen E, Rahman A et al. Damage and mortality in a group of British 
patients with systemic lupus erythematosus followed up for over 10 years. 
Rheumatology 2009; 48:673-5.  
2. Gladman DD, Urowitz MB, Keystone EC. Serologically active clinically quiescent 
systemic lupus erythematosus. Am J Med. 1979; 66:210-5.  
3. Ng K, Manson JJ, Rahman A, Isenberg DA. Association of antinucleosome antibodies 
with disease flare in serologically active clinically quiescent patients with systemic 
lupus erythematosus. Arthritis Care Res 2006; 55:400-4.  
4. Gladman DD, Goldsmith CG, Urowitz MB, et al. Sensitivity to change of 3 systemic 
lupus erythematosus disease activity indices: international validation. J Rheumatol 
1994; 21:1468-71. 
5. Liang M, Socher SA, Larsen MG at al. Reliability and validity of six systems for the 
clinical assessment of disease activity in systemic lupus erythematosus. Arthritis 
Rheum 1989;32:1107-8. 
6. Tan EM, Cohen AS, Fries JF. The 1982 revised criteria for the classification of systemic 
lupus erythematosus. Arthritis Rheum 1982; 25:1271-7. 
7. Gordon C, Sutcliffe N, Skan J et al. Definition and treatment of lupus flares measured 
by the BILAG index. Rheumatology 2003; 42:1372-1379. 
8. Dubois EL, Tuffanelli DL. Clinical manifestations of systemic lupus erythematosus. 
JAMA 1964; 190:104-11 
9. Tozman EC, Urowitz MB, Gladman DD. Prolonged complete remission in previously 
severe SLE. Ann Rheum Dis 1982; 41:39-40. 
10. Formiga F, Moga I, Pac M, et al. High disease activity at baseline does not prevent a 
remission in patients with systemic lupus erythematosus. Rheumatology 1999; 38:724-
7. 
11. Drenkard C, Villa AR, Garcia-Padilla A, et al. Remission of systemic lupus 
erythematosus. Medicine (Baltimore) 1996; 75:88-99. 
12. Heller CA, Schur PH. Serological and Clinical Remission in Systemic Lupus 
Erythematosus. J Rheumatol 1985; 12:916-8. 
13. Urowitz MB, Feletar M, Bruce IN et al. Prolonged Remission in Systemic Lupus 
Erythematosus. J Rheumatol 2005; 32:1467-1472. 
14. Tsakonas E, Joseph L, Esdaile JM, et al. A long-term study of hidroxicloroquine 
withdrawal on exacerbations in systemic lupus eruthematosus. The Canadian 
Hidroxicloroquine Study Group. Lupus 1998;7:80-5.  
15. Alarcón GS, McGwin G, Bertoli AM, et al. Effect of hydroxychloroquine on the survival 
of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US 
cohort (LUMINA L). Ann Rheum Dis 2007;66:1168-72. 
16. Steiman AJ, Gladman DD, Urowitz MB. Outcomes in patients with Systemic Lupus 
Erythematosus with and without a Prolonged Serologically Active Clinically Quiescent 
Period. Arthritis Care Res. 2012; 64:511-8.  
17. Van Vollenhoven RF, Mosca M, Bertsias G, Isenberg DA, et al. Treat-to-target in 
systemic lupus erythematosus recommendations from an international task force. Ann 
Rheum Dis 2014; 73:958-67. 
18. Hay EM, Bacon PA, Gordon C et al. The BILAG index: a reliable and valid instrument for 
measuring clinical disease activity in systemic lupus erythematosus. Q J med 1993; 
86:447-58. 
19. 19. Isenberg DA, Rahman A, Allen E et al. BILAG 2004 – Development and initial 
validation of an updated version of the British Isles Lupus Assessment Group’s disease 
activity index for patients with systemic lupus erythematosus. Rheumatology 2005; 44; 
902-6. 
20. Nossent JC. SLICC/ACR damage index in Afro-Caribbean patients with systemic lupus 
erythematosus: changes in and relationship to disease activity, corticosteroid therapy, 
and prognosis. J Rheumatol 1998; 25:654-9.  
21. Lopez R, Davidson JE, Beeby MD, Egger PJ, Isenberg DA. Lupus disease activity and the 
risk of subsequent organ damage and mortality in a large lupus cohort. Rheumatology 
2012; 51:491-8. 
22. Cooper GS, Treadwell EL, ST Clair EW,et al. Sociodemographic associations with early 
disease damage in patients with systemic lupus erythematosus. Arthritis Reum 2007; 
57:993-9.  
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
